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INTRODUCTION 
The oral route of drug delivery in general is considered 
the favourite means of drug administration. 
Conventional drug delivery systems for controlled 
release are based on single or multiple unit reservoir or 
matrix system. These are design to deliver constant 
drug levels over an extended period of time. Pulsatile 
systems are basically time controlled drug delivery 
systems which are designed to mimic the circadian 
rhythm of the body and deliver the drug at a specific 
time (after a programmed lag phase) as the 
pathophysiological conditions of disease required, 
resulting in improvement of patient compliance and 
therapeutic efficacy
1-5
. 
Need for study: 
Diabetes mellitus (DM) is characterized by high levels 
of blood glucose due to defects in insulin production, 
insulin action, or both. Type-II DM (non-insulin 
dependent diabetes mellitus) occurs due to insulin 
resistance and relative insulin deficiency. Oral 
sulfonylurea’s therapy remains a cornerstone for the 
treatment of diabetes.  Sulfonylurea’s acts through 
insulin release by inhibiting the KATP channel of the 
pancreatic ß-cells. Glipizide belongs to sulfonylurea 
class and is an oral rapid- and short-acting anti-diabetic 
drug. It is an effective oral anti-diabetic (100 times 
more potent than Tolbutamide in evoking pancreatic 
secretion of insulin)
6-8
. Owing to its short biological 
half life (3.4 ± 0.7 h), there is an urgent need of such a 
delivery system which can overcome its multidosing 
per day through delayed release and extended half life. 
Thus, development of multiunit pulsatile dosage form 
would be the advantageous. 
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ABSTRACT 
The objective of the present study was to fabricate and evaluate a chronomodulated pulsatile drug delivery system to maintain 
the blood glucose level by releasing the drug at a predetermined time interval. The basic design of the system consisted of a 
glipizide microspheres filled in a formaldehyde treated impermeable gelatin capsule body which is plugged with a bilayer tablet 
plug (glipizide in fast releasing layer and erodible polymer plug made of 20% guar gum). Plugs were prepared by direct 
compression method using super disintegrant (Croscarmellose) in fast releasing layer and different percentage of guar gum in 
erodible tablet layer. The microspheres were successfully prepared from ethylcellulose and eudragit using emulsification-
solvent evaporation method. Formaldehyde treated capsules, bilayered tablet plugs and microspheres were evaluated for various 
parameters. A chronomodulated pulsatile drug delivery system containing glipizide bilayer tablet and glipizide microspheres 
was prepared and was evaluated for weight variation and in vitro drug release studies. The results concluded the programmable 
pulsatile release has been achieved with modified pulsincap of Glipizide. Formulation FG-2, FG -5, FG -8 and FG -11 were 
chosen as best formulations. The dosage form can be taken half an hour before the breakfast and will deliver its first pulse as an 
immediate dose (5 mg) within 30 minutes and second pulse of sustained release microspheres (equivalent to 10 mg Glipizide) 
during noon which will maintain the drug concentration throughout the day till mid night and thus consistent with the demands 
of the chronotherapeutic drug delivery. 
Keywords: Pulsincap, chronomodulated, glipizide, guar gum, croscarmellose. 
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MATERIALS AND METHODS 
Materials: 
Glipizide was obtained as a gift sample from USV Ltd, 
Baddi. Ethyl cellulose and croscarmellose were procured 
from HiMedia Laboratories Pvt. Ltd., Mumbai. Eudragit 
S-100 and L-100 were obtained as a gift sample from 
Evonik Degussa India Private Limited, Mumbai. 
Disodium hydrogen phosphate, potassium dihydrogen 
phosphate, acetone, chloroform, petroleum ether and n-
Hexane were purchased from Merck India Pvt. Ltd., 
Mumbai. Guar gum, PVP, cellulose acetate phthalate, 
sodium hydroxide was purchased from CDH (P) Ltd., 
New Delhi. Lactose, magnesium stearate, sodium 
chloride, span-80 and tween-80 were procured from 
Loba Chemie Pvt. Ltd., Mumbai. 
Preparation of impermeable capsule body
9,10
: 
Hard gelatin capsules of size 0 were taken 50 in number. 
Their bodies were separated from the caps. 25 ml of 
15% v/v formaldehyde was taken into desiccator and a 
pinch of KMnO4 was added, to generate formalin 
vapours. The desiccator was tightly closed. The reaction 
was conducted for 12 hours; after which the capsule 
bodies were removed. The capsule bodies were dried for 
30 minutes at 50°C to ensure the completion of reaction 
between gelatin and formaldehyde vapours. To facilitate 
removal of residual formaldehyde the bodies were then 
dried at room temperature. Tests like identification 
attributes (transparency, lockable type, odour, nature), 
visual defects, dimensions and solubility studies of the 
treated capsules were conducted on prepared 
impermeable capsule body.  
Preparation of microspheres of Glipizide: 
Microspheres were prepared by using emulsification-
solvent evaporation method. Accurately weighed 1 gm 
polymer (Ethyl cellulose/Eudragit L-100:S-100) was 
dissolved in 100 ml of solvent (Chloroform/Acetone) to 
form a homogenous polymer solution. Core material, i.e. 
Glipizide was added to the polymer solution and mixed 
thoroughly. This organic phase was slowly poured into 
continuous phase (200 ml of aqueous phase containing 
emulsifier i.e.     0.5 %w/v of Sodium CMC / 200 ml of 
liquid paraffin) containing 1% w/w of surfactant 
(Tween-80/Span-80) with stirring at 1000 rpm to form a 
smooth emulsion. Thereafter, it was allowed to reach 
room temperature and stirring was continued until 
residual chloroform/acetone was evaporated and 
smooth-walls, rigid and discrete microspheres were 
formed. The microspheres were collected by decantation 
and the product was washed with water/petroleum ether 
(40-60°C), four times and dried at room temperature for 
3 hours. The microspheres were then stored in a 
desiccator over fused calcium chloride. 
Microspheres were evaluated for particle size (using 
optical microscopy), flow properties, surface 
morphology (SEM), percentage practical yield and 
percentage drug content. To carry out drug content, in a 
100 ml volumetric flask microspheres equivalent to 
10mg of Glipizide were taken and the volume was made 
up to mark with pH 6.8 phosphate buffer. The flask was 
shaken for 12 hours using a mechanical shaker. Then the 
solution was filtered and appropriate dilutions were 
made from the filtrate and absorbance was measured at 
226 nm. 
 
Table 1: Drug Polymer Ratio for Eudragit and Ethyl cellulose microspheres of Glipizide 
Ingredients Formulations 
GM-1 GM-2 GM-3 GM-4 
Glipizide 0.5 gm 1 gm 0.5 gm 1 gm 
Eudragit 1 gm 1 gm --- --- 
Span-80 2ml 2ml --- --- 
Liquid Paraffin 200 ml 200 ml --- --- 
Ethyl cellulose --- --- 1 gm 1 gm 
Tween-80 --- --- 2ml 2ml 
Aqueous solution (0.5%w/v 
Sodium CMC) 
--- --- 200 ml 200 ml 
 
 
Preparation of glipizide bilayered tablet plug: 
Bilayered tablet plugs of glipizide were prepared by the 
direct compression method. 
1. Formulation of the fast release layer: The dose of 
the formulation for fast release was 5mg. The 
polymers, drug and other excipients for fast 
releasing layers were passed through sieve #60 
before their use in the formulation. The blend is 
mixed properly. 
2. Formulation of erodible tablet layer: The 
formulations containing 16, 20 and 30% of Guar 
gum were prepared and excipients like lactose was 
added up to 99%. Each formulation was mixed for 
10 minutes, followed by addition of 1% magnesium 
stearate to each blend. The resultant blends were 
mixed for 5 minutes. 
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Table 2: The composition of Bilayer Tablet Plugs  
     Formulation 
 
Ingredients 
G-1 
(mg) 
G-2 
(mg) 
G-3 
(mg) 
G-4 
(mg) 
G-5 
(mg) 
G-6 
(mg) 
G-7 
(mg) 
G-8 
(mg) 
G-9 
(mg) 
G-10 
(mg) 
G-11 
(mg) 
G-12 
(mg) 
Fast Release Layer 
Glipizide 5 5 5 5 5 5 5 5 5 5 5 5 
MCC --- 86 85 84 --- 86 85 84 --- 86 85 84 
Croscarmellose 
sodium 
---- 4 5 6 ---- 4 5 6 ---- 4 5 6 
PVP K-30 --- 3 3 3 --- 3 3 3 --- 3 3 3 
Aerosil --- 1 1 1 --- 1 1 1 --- 1 1 1 
Lactose 66 --- --- --- 66 --- --- --- 66 --- --- --- 
Starch 25 --- --- --- 25 --- --- --- 25 --- --- --- 
Mg. Stearate 2 1 1 1 2 1 1 1 2 1 1 1 
Talc 2 --- --- --- 2 --- --- --- 2 --- --- --- 
Amaranth q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Erodible Tablet Layer 
Guar Gum 32 32 32 32 40 40 40 40 60 60 60 60 
Lactose 164 164 164 164 156 156 156 156 136 136 136 136 
Mg. Stearate 4 4 4 4 4 4 4 4 4 4 4 4 
 
3. Compression of bilayered tablet plugs: The 
blends of erodible tablet plug containing 16, 20 and 
30% of Guar Gum were separately compressed 
lightly using a Rotary Tablet Compression Machine 
using 6.5 mm round, flat and plain punches. Over 
this compressed layer, required quantity of the fast 
release layer containing drug was placed and 
compressed (hardness in the range of 4.5-5.5 
kg/cm
2
) to form a Glipizide Bilayered Tablet Plugs. 
The composition of all formulations is provided in 
table 2. 
Pre-compression Studies were conducted. Compressed 
bilayered tablet plugs were evaluated for parameters like 
hardness, weight variation, uniformity of thickness, 
friability test, erosion time, percentage drug content and 
in vitro drug release studies. 
Assembly of pulsatile drug delivery system 
containing glipizide
11,12
: 
 
Figure 1: Overview of designed pulsatile device 
A chronomodulated Pulsatile (modified pulsincap) drug 
delivery system containing Glipizide Bilayer Tablet and 
Glipizide microspheres was prepared for the time-
controlled release of both drugs in combination. 
Overview of designed pulsatile device is shown in 
Figure 01. 
Procedure for assembly of pulsatile (modified 
pulsincap) drug delivery system: 
Formaldehyde treated hard gelatin capsules of size ‘0’ 
were chosen for the formulation. The bodies and caps 
were separated manually. Microspheres equivalent to 10 
mg of Glipizide and lactose was filled in capsule body 
and then plugged with bilayered tablet plugs containing 
Guar Gum of various compositions and then capped 
with soluble gelatin cap. The whole system thus 
produced is modified pulsincap. 
Glipizide bilayered tablet plug containing fast releasing 
layer (5 mg glipizide and five percent croscarmellose 
sodium as super disintegrant) and erodible tablet layer 
containing 16%, 20% and 30% of Guar Gum has been 
used for preparing pulsatile (modified pulsincap) drug 
delivery system containing Glipizide microspheres 
(equivalent to 10 mg). 
In bilayered tablet layer, there will be fast release of 
Glipizide (5 mg) followed by a slow erodible polymer 
(guar gum). Sampling was stopped after 0.5 hours (i.e. 
after release of Glipizide from fast releasing layer) and 
again started 0.5 hours before the expelling time of 
plugs (i.e. sampling started after 4, 5 and 6.5 hour for 
formulations containing 16%, 20% and 30% guar gum 
plug respectively). The composition for modified 
pulsatile device containing Glipizide Bilayer tablet and 
Glipizide microspheres is illustrated in the following 
table 3. Formulation FG-1 to FG-3, FG-4 to FG-6, FG-7 to 
FG-9 and FG-10 to FG-12 contains Glipizide: 
Ethylcellulose (0.5:1), Glipizide: Ethylcellulose (1:1), 
Glipizide: Eudragit (0.5:1) and Glipizide:Eudragit 
(0.5:1) respectively. 
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Table 3: Composition for modified pulsatile device containing Glipizide microspheres  
Batch 
code 
Wt. of 
empty 
body (mg) 
Wt. of 
Microspheres 
(mg)
 
Percentage of 
Guar Gum 
used in plugs 
Lactose Total wt. of assembled 
capsule after CAP 
coating (mg) 
FG-1 43.0 31 16% 200 622 
FG-2 41.0 31 20% 200 620 
FG-3 43.0 31 30% 200 623 
FG-4 39.0 21 16% 200 611 
FG-5 40.0 21 20% 200 609 
FG-6 41.0 21 30% 200 608 
FG-7 41.0 31 16% 200 619 
FG-8 43.0 31 20% 200 621 
FG-9 42.0 31 30% 200 620 
FG-10 43.0 21 16% 200 608 
FG-11 42.0 21 20% 200 610 
FG-12 41.0 21 30% 200 607 
 
Stability Studies
13
: 
ICH Tripartite Guidelines have established that long 
term stability testing should be done at 25°C / 60% RH; 
stress testing should be done at 40°C / 75% RH for 6 
months. If significant change occurs at these stress 
conditions, then the formulation should be tested at an 
intermediate condition i.e. 30°C / 75% RH. 
RESULT AND DISCUSSIONS 
Impermeable capsule body 
Impermeable capsule body was successfully obtained. 
Formaldehyde treated empty capsules were evaluated 
for various parameters and results are as follows:- 
1. Identification attributes: They were no significant 
changes in the capsules except for the stickiness. 
2. Visual defects: In about 50 capsule bodies treated 
with formaldehyde five were found to shrink or 
distorted. 
3. Dimensions: The ‘0’ size capsule bodies showed a 
significant decrease in length and diameter. The 
following measurements were taken before and 
after formaldehyde treatment of capsule body. 
Average capsule length: 
 Before formaldehyde treatment (untreated cap and 
body): 18.5 ± 0.101 mm 
 After formaldehyde treatment (treated body and 
untreated cap): 17.5 ± 0.116 mm  
Average diameter of capsule body: 
 Before formaldehyde treatment: 6.5 ± 0.097 mm 
 After formaldehyde treatment: 6.3 ± 0.072 mm 
Average length of capsule body: 
 Before formaldehyde treatment: 16.0 ± 0.088 mm 
 After formaldehyde treatment: 15.0 ± 0.069 mm 
4. Solubility studies for the treated capsules: The 
treated capsules were subjected to solubility studies 
for 24 hours in different buffers, the following 
observations were made: 
 In the case of normal capsules, both cap and body 
dissolved within 15 minutes. 
 In the case of formaldehyde treated capsules, the 
cap dissolved within 15 minutes; whereas the 
capsule remained intact for about 24 hours. This 
was attributable to the cross linking of gelatin 
which prevented the disintegration of the capsule 
body. 
Microspheres of glipizide 
Microspheres were successfully prepared. The prepared 
microspheres were examined under an optical 
microscope. From SEM (Figure 02), it was observed 
that the prepared microspheres were spherical with 
smooth surface; might be due to complete homogeneity 
of drug and polymers. Eudragit microspheres had mean 
particle size of ranged between 30-55 μm; while the 
ethylcellulose microspheres were ranged between 38-61 
μm. 
 
Figure 2: Scanning Electron Micrographs of glipizide 
microspheres  
a) GL-1,  b) GL-2,  c) GL-3 and  d) GL-4 
Results of flow property, percentage yields and 
percentage drug content of glipizide microspheres are 
shown in table 4. All the formulations showed good 
flow properties. The value of the angle of repose 
between 21-28°θ indicates that the flow of the particles 
was reasonable and the microspheres were found to be 
fit in respect to flow ability and were thus suitable for 
further processing in the filling of the capsules. The 
mean percentage practical yield for all the formulation 
GM -1 to 4 was greater than 91%. It was observed that 
there was a positive correlation between the solid 
content and the percentage yield, which can be 
explained by the fact that, though a constant material is 
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always lost in processing. This loss is proportionately 
less significant when the solid content is more. The drug 
content was found to be very high in all the cases i.e. all 
the formulations showed percentage drug content in the 
range of 96-98%. 
 
Table 4: Flow property, % yields and % drug content of Glipizide microspheres 
Formulation Angle of Repose* % Drug content* % Yield* 
GM -1 28.83 ± 0.5830 98.38 ± 0.7378 93.11 ± 0.5639 
GM -2 23.17 ± 0.6740 97.51 ± 0.5682 91.68 ± 0.8392 
GM -3 25.79 ± 0.4317 96.74 ± 0.4973 94.42 ± 1.0523 
GM-4 21.51 ± 0.4842 96.49 ± 0.6119 92.74 ± 0.3850 
*Each value is the mean ± SD; n=3 
Bilayered tablet plugs 
Bilayered Tablet Plugs were successfully prepared by 
direct compression method. Tablets were then stored in 
a desiccators over fused calcium chloride till further 
evaluations. The results of pre-compression studies are 
presented in table 5 and it shows that the results 
obtained for all formulations are in conformity with 
their flow rates. Both Hausner’s ratio and Carr’s index 
of all formulations indicate good and excellent flow 
respectively.  
The measured hardness of tablets of all formulations 
ranged between 5.28 ± 0.1643 to 5.46 ± 0.1342 Kg/cm
2
. 
These ensure good handling characteristics of all 
batches. All the formulated plugs passed the test as the 
percentage weight variation was within the 
pharmacopoeial limits. It was found out; the weights of 
all tablets were uniform with low standard deviation 
values. Thickness of tablets was found in a range 5.97 ± 
0.0891 mm to 6.04 ± 0.1350 mm. The percentage 
friability was less than one percent in all formulations, 
indicating is within the prescribed limits. The results of 
friability indicate that the tablets possess good 
mechanical strength. A result of erosion 
time/disintegration time is shown in table 6. From 
erosion time, it was found Guar Gum disintegrate slowly 
and take more time to erode as compared to other 
formulations. Among all the formulations, formulations 
containing 16% Guar Gum tablet plugs erode fast than 
others because of less concentration of this polymer. It 
was observed as the concentration of polymer increases 
erosion time increases. The content of Glipizide in each 
preparation was assayed by UV spectroscopy. The drug 
content was found to be very high in all the cases in a 
range between 96.6 ± 0.1643% to 99.2 ± 0.0512%. The 
assay values were between 95% and 98% of the 
theoretical values. 
 
Table 5: Pre-compression studies of fast releasing layer 
Bulk density* (gm/ml)  Tapped density* (gm/ml) Carr’s index* (%) Hausner ratio* Angle of repose* (˚θ) 
Fast releasing layer containing Glipizide lactose granules (G-1, G-5, G-9) 
0.461 ± 0.011 0.566 ± 0.006 18.44 ± 1.305 1.226 ± 0.012 26.630 ± 0.872 
Fast releasing layer containing 4% Croscarmellose (G-2, G-6, G-9) 
0.415 ± 0.016 0.498 ± 0.009 16.60 ± 0.739 1.199 ± 0.017 25.712 ± 0.683 
Fast releasing layer containing 5% Croscarmellose (G-3, G-7, G-11) 
0.444 ± 0.026 0.544 ± 0.011 18.23 ± 0.928 1.223 ± 0.026 26.787 ± 0.914 
Fast releasing layer containing 6% Croscarmellose (G-4, G-8, G-12) 
0.437 ± 0.019 0.529 ± 0.015 17.46 ± 1.218 1.212 ± 0.031 27.163± 0.846 
*Average ± SD of 3 determinations 
Table 6: Results of erosion time and percentage drug content of different formulations of bilayered tablet plug 
Code Erosion Time of Fast releasing layer  
(Coloured Layer) (min) 
Erosion Time of Erodible 
polymer layer (hr) 
Percentage Drug 
content* (%) 
G-1 3.59 ± 0.151 4.54 ± 0.392 97.2 ± 0.2859 
G-2 0.85 ± 0.253 4.56 ± 0.288 96.6 ± 0.1643 
G-3 0.67 ± 0.121 4.59 ± 0.153 99.2 ± 0.1305 
G-4 1.27 ± 0.163 4.52 ± 0.034 98.3 ± 0.0797 
G-5 3.62 ± 0.142 5.62 ± 0.191 98.4 ± 0.1014 
G-6 0.85 ± 0.211 5.58 ± 0.113 98.6 ± 0.0512 
G-7 0.65 ± 0.194 5.59 ± 0.218 98.2 ± 0.0568 
G-8 1.29 ± 0.136 5.61 ± 0.104 98.4 ± 0.0960 
G-9 3.83 ± 0.294 6.63 ± 0.099 97.6 ± 0.0911 
G-10 0.83 ± 0.183 6.62 ± 0.111 97.2 ± 0.1190 
G-11 0.65 ± 0.314 6.61 ± 0.429 98.8 ± 0.0854 
G-12 1.28 ± 0.384 6.65 ± 0.183 99.2 ± 0.0512 
*Average ± SD of 3 determinations 
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In vitro drug release studies were performed using USP-
XXIII dissolution assembly. In vitro percentage drug 
release data are given in table 7. In vitro dissolution 
studies of formulations containing Glipizide lactose 
granules (starch as a disintegrant) were carried out and it 
showed approximately 98% of drug release after 30 
minutes. Among all the formulations, formulations 
containing super disintegrant croscarmellose five percent 
show fast drug release than other formulations. 
Croscarmellose swells faster and cause fast 
disintegration of tablets. It was observed that the 
formulations containing croscarmellose six percent show 
slower release of drug. This is due to the reason that 
croscarmellose is effective at low concentrations only 
(0.5-5%)
14
. 
 
Table 7: Percentage Cumulative Drug Release data of Glipizide from formulations 
Time 
(min) 
Percentage Cumulative Drug Release
*
 
G-1 G-2 G-3 G-4 G-5 G-6 G-7 G-8 G-9 G-10 G-11 G-12 
0 00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
00.00 
± 0.00 
2.5 18.89 
± 0.25 
38.88 
± 0.36 
43.19 
± 0.26 
32.21 
± 0.47 
19.43 
± 0.03 
39.04 
± 0.15 
42.97 
± 0.45 
31.91 
± 0.59 
18.56 
± 0.30 
38.04 
± 0.15 
42.32 
± 0.28 
32.08 
± 0.65 
5 33.49 
± 0.13 
60.36 
± 0.35 
65.78 
± 0.23 
52.20 
± 0.39 
33.64 
± 0.41 
59.98 
± 1.46 
66.18 
± 0.51 
55.69 
± 0.64 
32.78 
± 0.33 
59.08 
± 0.96 
65.51 
± 0.47 
51.95 
± 0.66 
10 53.10 
± 0.17 
79.20 
± 0.47 
88.23 
± 0.35 
71.09 
± 0.28 
54.12 
± 0.51 
78.84 
± 0.64 
89.03 
± 0.56 
71.54 
± 0.42 
52.26 
± 0.37 
79.61 
± 0.87 
87.88 
± 0.57 
70.83 
± 0.52 
15 68.55 
± 0.83 
89.95 
± 0.26 
96.61 
± 0.24 
83.99 
± 0.39 
69.05 
± 0.31 
89.15 
± 0.20 
96.74 
± 0.58 
83.71 
± 0.40 
67.71 
± 0.42 
89.94 
± 0.32 
95.56 
± 0.44 
83.56 
± 0.42 
20 80.31 
± 0.18 
95.38 
± 0.29 
99.59 
± 0.41 
91.00 
± 0.42 
80.63 
± 0.20 
94.86 
± 0.47 
99.55 
± 0.09 
90.46 
± 0.57 
81.05 
± 0.29 
95.21 
± 0.24 
99.15 
± 0.37 
90.53 
± 0.30 
25 90.28 
± 0.29 
99.27 
± 0.13 
--- 96.90 
± 0.19 
90.81 
± 0.14 
99.61 
± 0.16 
--- 97.23 
± 0.53 
90.02 
± 0.39 
99.36 
± 0.33 
--- 97.15 
±0.67 
30 98.02 
± 0.58 
--- --- --- 98.26 
± 0.63 
--- --- --- 98.67 
± 0.45 
--- --- --- 
*Average ± SD of 3 determinations 
 
Pulsatile (modified pulsincap) drug delivery system 
containing glipizide  
Pulsatile drug delivery system of Anti-Diabetic Drug 
(Glipizide) was successfully prepared. All the 
formulated capsules passed the test since the percentage 
weight variation was within the pharmacopoeial limits. 
In vitro dissolution profile of pulsincap formulations 
during 16 hours studies was found to have an efficient 
time controlled release of Glipizide.  
 
Figure 3: In vitro drug release profile of formulation 
FG-1 to FG-3 
The percentage cumulative drug release for all 
formulations (FAL-1 to FAL-12) is illustrated in Figure 
03-06. It was observed that the fast releasing layer of 
Bilayered tablet plug shows in vitro release of 5 mg of 
drug within 30 minutes and later the drug release from 
Glipizide microspheres occur after a lag time period of 
4.5-7 hours. 
 
 
Figure 4: In vitro drug release profile of formulation 
FG-4 to FG-6 
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Figure 5: In vitro drug release profile of formulation 
FG-7 to FG-9 
 
Figure 6: In vitro drug release profile of formulation 
FG-10 to FG-12 
The drug release from the formulations was dependent 
on the type of hydrogel plug present in the Pulsincap 
device. The formulations with the plug with 30% Guar 
Gum showed more lag time 7 hours this was due to the 
higher viscosity of Guar Gum which swell slowly and to 
a greater extend producing a viscous gel which holds the 
capsule body for a longer time as compared to the 
hydrogel plugs containing 16% guar gum plugs which 
takes up water fast, disintegrates faster and showed less 
lag time of 4.5 hours.  
During dissolution studies, it was observed that, after 
the releases of immediate dose of Glipizide (5 mg) from 
bilayered tablet plug in simulated gastric fluid; the 
exposed polymer plug start absorbing the surrounding 
fluids, swollen and released the drug through the 
swollen matrix. After complete wetting of the plug, it 
formed a soft mass and then easily ejected out of the 
capsule body; releasing the Glipizide microspheres into 
the simulated colonic fluid with pH 6.8. Among all the 
formulations, formulations containing Glipizide: 
Eudragit 0.5:1 microspheres (FG-7 to FG-9) showed slow 
drug releases after controlled lag time. 
Based on the in vitro drug release data, considering the 
highest regression values the best fitting model for 
Glipizide in all formulations was Higuchi-Matrix with 
an exception of FG-9 where First order was the best 
fitting model for Glipizide. 
Stability Studies 
The results of stability studies of Glipizide Pulsatile 
drug delivery system showed no significant change with 
respect to physical appearance, drug content and in vitro 
drug release at the end of six months. Aging did not 
alter the drug release profiles of any of the formulations 
significantly at the end of the storage period. 
CONCLUSION 
In the present study, a time-controlled chronomodulated 
pulsatile drug delivery system of Glipizide containing an 
immediate release dose and Glipizide microspheres for 
sustained release of the drug after a desired lag time was 
successfully developed.  It has been concluded from the 
investigation that pulsincap dosage form of glipizide 
could be effectively control the blood glucose levels 
throughout the day in respect to release of two pulses 
i.e. first pulse of immediate dose (equivalent to 5 mg 
Glipizide) after administration before breakfast and 
second pulse of sustained release microspheres 
(equivalent to 10 mg Glipizide) during noon which will 
maintain the drug concentration throughout the day till 
mid night. Hence it is considered to be suitable for the 
diabetic patient to manage postprandial blood glucose 
levels. 
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